Navigation Links
Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Date:9/6/2011

NEW YORK, Sept. 6, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity

http://www.reportlinker.com/p0610886/Licensing-Strategies-of-Large-Pharmaceutical-Companies---Weak-RD-Pipelines-and-the-Patent-Cliff-Stimulate-In-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity

Summary

GBI Research has released its latest research, "Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity" which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes -

- Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry

- Trends in deals for product licensing and technology licensing agreements.

- Extensive research and analysis of the licensing activity of large pharmaceutical companies.

- Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value

- Company profiles of leading biotech companies active in licensing and deal making

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the pharmaceutical industry.

- Enable better product lifecycle management by identifying key phases of product licensing agreements.

- Develop segment specific strategies for licensing and deal making in pharmaceutical industry.

- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading pharma companies.

- Accelerate and strengthen your market position by identifying key companies for licensing agreements.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 8

2 Licensing Strategies In Large Pharmaceutical Companies – Introduction 13

2.1 Licensing Agreement – An Authorization 13

2.2 GBI Research Report Guidance 15

3 Trends in In-licensing and Out-licensing Agreements 16

3.1 In-Licensing Compensates For Declining Internal R&D 16

3.2 Licensing Key To Combat Patent Cliff 16

3.3 Spiraling Cost of Licensing Deals 16

3.3.1 Competition to Restock Pipelines 16

3.3.2 Biotechs Push Products through Further Stages of Development 16

4 Product Licensing 18

4.1 Licensing Offsets Deficiencies in Internal Pipelines and Portfolios 18

4.2 Oncology Therapy Area Spearheads Licensing Agreements in Big Pharma Companies 18

4.3 Licensing Deals in Asia-Pacific on the Rise 19

5 Technology Licensing Deals 20

5.1 Importance of Technology In-Licensing 20

5.2 Technology Licensing With Universities 20

6 Major Licensing Deals of Big Pharma Companies – 2010 21

6.1 High Value Deals of Big Pharma Players – 2010 21

6.1.1 GlaxoSmithKline Enters Into Licensing Agreement with Isis Pharmaceuticals 21

6.1.2 Sanofi-Aventis enters Into Licensing Agreement with Avila Therapeutics 22

6.1.3 Boehringer Ingelheim Enters into Licensing Agreement With f-star Biotechnologische 22

6.1.4 Merck Amends Its Collaboration Agreement with Ariad Pharmaceuticals 23

6.1.5 AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals 23

7 Licensing Strategies of Major Pharma Companies 24

7.1 GlaxoSmithKline 24

7.1.1 Overview 24

7.1.2 Licensing Agreements – GSK 24

7.1.3 By Value 25

7.1.4 By Type 27

7.1.5 By Geography 28

7.1.6 By Therapy Area 29

7.1.7 By Phase 30

7.2 J&J 31

7.2.1 Overview 31

7.2.2 Licensing Agreements – J&J 31

7.2.3 By Value 32

7.2.4 By Type 34

7.2.5 By Geography 35

7.2.6 By Therapy Area 36

7.2.7 By Phase 37

7.3 Roche 38

7.3.1 Overview 38

7.3.2 Licensing Agreements – Roche 38

7.3.3 By Value 39

7.3.4 By Type 41

7.3.5 By Geography 42

7.3.6 By Therapy Area 43

7.3.7 By Phase 44

7.4 Abbott 45

7.4.1 Overview 45

7.4.2 Licensing Agreements – Abbott 45

7.4.3 By Value 46

7.4.4 By Type 47

7.4.5 By Geography 48

7.4.6 By Therapy Area 49

7.4.7 By Phase 50

7.5 Eli Lilly 51

7.5.1 Overview 51

7.5.2 Licensing Agreements – Eli Lilly 51

7.5.3 By Value 52

7.5.4 By Type 54

7.5.5 By Geography 55

7.5.6 By Therapy Area 56

7.5.7 By Phase 57

7.6 Novartis 58

7.6.1 Overview 58

7.6.2 Licensing Agreements – Novartis 58

7.6.3 By Value 59

7.6.4 By Type 61

7.6.5 By Geography 62

7.6.6 By Therapy Area 63

7.6.7 By Phase 64

7.7 Sanofi 65

7.7.1 Overview 65

7.7.2 Licensing Agreements – Sanofi 65

7.7.3 By Value 66

7.7.4 By Type 68

7.7.5 By Geography 69

7.7.6 By Therapy Area 70

7.7.7 By Phase 71

7.8 Takeda 72

7.8.1 Overview 72

7.8.2 Licensing Agreements – Takeda 72

7.8.3 By Value 74

7.8.4 By Type 75

7.8.5 By Geography 75

7.8.6 By Therapy Area 76

7.8.7 By Phase 77

7.9 Pfizer 78

7.9.1 Overview 78

7.9.2 Licensing Agreements – Pfizer 78

7.9.3 By Value 79

7.9.4 By Type 81

7.9.5 By Geography 82

7.9.6 By Therapy Area 83

7.9.7 By Phase 84

7.10 Bristol-Myers Squibb 85

7.10.1 Overview 85

7.10.2 Licensing Agreements – Bristol-Myers Squibb 85

7.10.3 By Value 86

7.10.4 By Type 88

7.10.5 By Geography 89

7.10.6 By Therapy Area 90

7.10.7 By Phase 91

7.11 Boehringer-Ingelheim 92

7.11.1 Overview 92

7.11.2 Licensing Agreements – Boehringer Ingelheim 92

7.11.3 By Value 93

7.12 Merck & Co. 94

7.12.1 Overview 94

7.12.2 Licensing Agreements – Merck & Co. 94

7.12.3 By Value 95

7.12.4 By Type 97

7.12.5 By Geography 98

7.12.6 By Therapy Area 99

7.12.7 By Phase 100

7.13 Bayer 101

7.13.1 Overview 101

7.13.2 Licensing Agreements – Bayer 101

7.13.3 By Value 102

7.13.4 By Type 104

7.13.5 By Geography 105

7.13.6 By Therapy Area 106

7.13.7 By Phase 107

7.14 AstraZeneca 108

7.14.1 Overview 108

7.14.2 Licensing Agreements – AstraZeneca 108

7.14.3 By Value 109

7.14.4 By Type 111

7.14.5 By Geography 112

7.14.6 By Therapy Area 113

7.14.7 By Phase 114

7.15 Astellas 115

7.15.1 Overview 115

7.15.2 Licensing Agreements – Astellas 115

7.15.3 By Value 116

7.15.4 By Type 118

7.15.5 By Geography 119

7.15.6 By Therapy Area 120

7.15.7 By Phase 121

7.16 Daiichi-Sankyo 122

7.16.1 Overview 122

7.16.2 Licensing Agreements – Daiichi Sankyo 122

7.16.3 By Value 123

7.16.4 By Type 124

7.16.5 By Geography 125

7.16.6 By Therapy Area 126

7.16.7 By Phase 127

7.17 Teva Pharma 128

7.17.1 Overview 128

7.17.2 Licensing Agreements – Teva 128

7.17.3 By Value 129

7.17.4 By Geography 132

7.17.5 By Therapy Area 132

7.17.6 By Phase 133

7.18 Eisai 134

7.18.1 Overview 134

7.18.2 Licensing Agreements – Eisai 134

7.18.3 By Value 135

7.18.4 By Type 136

7.18.5 By Geography 137

7.18.6 By Therapy Area 138

7.18.7 By Phase 139

7.19 Baxter 140

7.19.1 Overview 140

7.19.2 Licensing Agreements – Baxter 140

7.19.3 By Value 141

7.19.4 By Type 142

7.19.5 By Therapy Area 143

7.20 Amgen 144

7.20.1 Overview 144

7.20.2 Licensing Agreements – Amgen 144

7.20.3 By Value 145

7.20.4 By Geography 146

7.20.5 By Therapy Area 147

7.20.6 By Phase 148

8 Licensing Strategies In Large Pharmaceutical Companies – Appendix 149

8.1 Market Definitions 149

8.2 Abbreviations 149

8.3 Research Methodology 149

8.3.1 Coverage 150

8.3.2 Secondary Research 150

8.3.3 Primary Research 150

8.3.4 Expert Panel Validation 151

8.4 Section Wise Methodology 151

8.4.1 Trends in In-licensing and Out-licensing Agreements 151

8.4.2 Product Licensing 151

8.4.3 Technology Licensing Deals 151

8.4.4 Major Licensing Deals of Big Pharma Companies – 2010 152

8.4.5 Licensing Strategies of Major Pharmaceutical Companies 152

8.5 Contact Us 152

8.6 Disclaimer 152

8.7 Sources 153

1.1 List of Tables

Table 1: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Value 2004–2010 17

Table 2: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Value, 2006–2010 25

Table 3: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2006 – 2010 32

Table 4: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2006–2010 39

Table 5: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Value, 2006–2010 52

Table 6: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Value, 2006–2010 59

Table 7: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Value, 2006 – 2010 66

Table 8: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Value, 2006 – 2010 73

Table 9: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2006 – 2010 79

Table 10: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2006 – 2010 86

Table 11: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Value, 2006–2010 95

Table 12: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010 102

Table 13: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006 – 2010 109

Table 14: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010 116

Table 15: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2006 – 2010 129

1.2 List of Figures

Figure 1: Licensing Strategies in Large Pharmaceutical Companies , Pharmaceutical Licensing Life Cycle, 2010 13

Figure 2: Licensing Strategies in Large Pharmaceutical Companies, Top 20 Pharmaceuticals Licensing Deals, 2005–2010 14

Figure 3: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Value, 2004–2010 17

Figure 4: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Therapy Area, 2010 18

Figure 5: Licensing Strategies in Large Pharmaceutical Companies, Top 20 Pharmaceutical Companies, Number of Licensing Deals, 2010 21

Figure 6: Licensing Strategies in Large Pharmaceutical Companies, GSK, Number of Licensing Deals, 2005 – Q1 2011 24

Figure 7: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Value, 2006–2010 25

Figure 8: Licensing Strategies in Large Pharmaceutical Companies, GSK, Number of Licensing Deals By Value, 2005 – Q1 2011 26

Figure 9: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Type, 2009 – Q1 2011 27

Figure 10: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Geography, 2009 – Q1 2011 28

Figure 11: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Therapy Area, 2009–Q1 2011 29

Figure 12: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Phase, 2009 – Q1 2011 30

Figure 13: Licensing Strategies in Large Pharmaceutical Companies, J&J, Number of Licensing Deals, 2005–Q1 2011 31

Figure 14: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2006–2010 32

Figure 15: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2005 – Q1 2011 33

Figure 16: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Type, 2009 – Q1 2011 34

Figure 17: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Geography 2009 – Q1 2011 35

Figure 18: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Therapy Area, 2009 – Q1 2011 36

Figure 19: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Phase, 2009 – Q1 2011 37

Figure 20: Licensing Strategies in Large Pharmaceutical Companies, Roche, Number of Licensing Deals, 2005 – Q1 2011 38

Figure 21: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2006–2010 39

Figure 22: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2005 – Q1 2011 40

Figure 23: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Type, 2009–Q1 2011 41

Figure 24: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Geography, 2009 – Q1 2011 42

Figure 25: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Therapy Area, 2009 – Q1 2011 43

Figure 26: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Phase, 2009 – Q1 2011 44

Figure 27: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Number of Licensing Deals, 2005 – 2010 45

Figure 28: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Number of Licensing Deals, By Value, 2005–2010 46

Figure 29: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Type, 2009 – Q1 2011 47

Figure 30: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Geography 2009 – Q1 2011 48

Figure 31: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Therapy Area, 2009 – Q1 2011 49

Figure 32: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Phase, 2009 – Q1 2011 50

Figure 33: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Number of Licensing Deals, 2005 – Q1 2011 51

Figure 34: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Value, 2006–2010 52

Figure 35: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Number of Licensing Deals, By Value, 2005 – Q1 2011 53

Figure 36: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Type, 2009 – Q1 2011 54

Figure 37: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Geography, 2009 – Q1 2011 55

Figure 38: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Therapy Area, 2009 – Q1 2011 56

Figure 39: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Phase, 2009 – Q1 2011 57

Figure 40: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Number of Licensing Deals, 2005 – Q1 2011 58

Figure 41: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Value, 2006–2010 59

Figure 42: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Number of Licensing Deals By Value, 2005 – Q1 2011 60

Figure 43: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Type, 2009 – Q1 2011 61

Figure 44: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Geography, 2009 – Q1 2011 62

Figure 45: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Therapy Area, 2009 – Q1 2011 63

Figure 46: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Phase, 2009 – Q1 2011 64

Figure 47: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Number of Licensing Deals, 2005 – Q1 2011 65

Figure 48: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Value, 2006 – 2010 66

Figure 49: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Number of Licensing Deals, By Value, 2005 – Q1 2011 67

Figure 50: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Type, 2009 – Q1 2011 68

Figure 51: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Geography, 2009 – Q1 2011 69

Figure 52: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Therapy Area, 2009 – Q1 2011 70

Figure 53: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Phase, 2009 – Q1 2011 71

Figure 54: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Number of Licensing Deals, 2005 – Q1 2011 72

Figure 55: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Value, 2006 – 2010 73

Figure 56: Licensing Strategies in Large Pharmaceutical Companies, Takedak Number of Licensing Deals, By Value, 2005 – Q1 2011 74

Figure 57: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Type, 2009 – Q1 2011 75

Figure 58: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Geography, 2009 – Q1 2011 75

Figure 59: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Therapy Area, 2009 – Q1 2011 76

Figure 60: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Phase, 2009 – Q1 2011 77

Figure 61: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Number of Licensing Deals, 2005 – Q1 2011 78

Figure 62: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2006–2010 79

Figure 63: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2005 – Q1 2011 80

Figure 64: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Type, 2009 – Q1 2011 81

Figure 65: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Geography, 2009 – Q1 2011 82

Figure 66: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Therapy Area, 2009 – Q1 2011 83

Figure 67: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Phase, 2009 – Q1 2011 84

Figure 68: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Number of Licensing Deals, 2005 – Q1 2011 85

Figure 69: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2006–2010 86

Figure 70: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2005 – Q1 2011 87

Figure 71: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Type, 2009 – Q1 2011 88

Figure 72: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Geography, 2009 – Q1 2011 89

Figure 73: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Therapy Area, 2009 – Q1 2011 90

Figure 74: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Phase, 2009 – Q1 2011 91

Figure 75: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Number of Licensing Deals, 2005 – Q1 2011 92

Figure 76: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Licensing Deals By Value, 2005 – 2010 93

Figure 77: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, 2005 – Q1 2011 94

Figure 78: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals, By Value, 2006–2010 95

Figure 79: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, By Value, 2005 – Q1 2011 96

Figure 80: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Type, 2009 – Q1 2011 97

Figure 81: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Geography, 2009 – Q1 2011 98

Figure 82: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Therapy Area, 2009 – Q1 2011 99

Figure 83: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Phase, 2009 – Q1 2011 100

Figure 84: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Number of Licensing Deals, 2005 – Q1 2011 101

Figure 85: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010 102

Figure 86: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2005 – Q1 2011 103

Figure 87: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Type, 2009 – Q1 2011 104

Figure 88: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Geography, 2009 – Q1 2011 105

Figure 89: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Therapy Area, 2009 – Q1 2011 106

Figure 90: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Phase, 2009 – Q1 2011 107

Figure 91: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals, 2005 – Q1 2011 108

Figure 92: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006–2010 109

Figure 93: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals By Value, 2005 – 2010 110

Figure 94: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Type, 2009 – Q1 2011 111

Figure 95: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Geography, 2009 – Q1 2011 112

Figure 96: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Therapy Area, 2009 – Q1 2011 113

Figure 97: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Phase 2009 – Q1 2011 114

Figure 98: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals, 2005 – Q1 2011 115

Figure 99: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010 116

Figure 100: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals By Value, 2005 – Q1 2011 117

Figure 101: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Type, 2009 – Q1 2011 118

Figure 102: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Geography, 2009 – Q1 2011 119

Figure 103: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Therapy Area, 2009 – Q1 2011 120

Figure 104: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Phase, 2009 – Q1 2011 121

Figure 105: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Number of Licensing Deals, 2005 – Q1 2011 122

Figure 106: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Number of Licensing Deals By Value, 2005 – Q1 2011 123

Figure 107: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Type, 2009 – Q1 2011 124

Figure 108: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Geography, 2009 – Q1 2011 125

Figure 109: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals by Therapy Area, 2009 – Q1 2011 126

Figure 110: Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Phase, 2009 – Q1 2011 127

Figure 111: Licensing Strategies in Large Pharmaceutical Companies, Teva, Number of Licensing Deals, 2005 – Q1 2011 128

Figure 112: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2006 – 2010 129

Figure 113: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2005 – Q1 2011 130

Figure 114: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Type, 2009 – Q1 2011 131

Figure 115: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Geography, 2009 – Q1 2011 132

Figure 116: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Therapy Area, 2009 – Q1 2011 132

Figure 117: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Phase, 2009 – Q1 2011 133

Figure 118: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Number of Licensing Deals, 2005 – Q1 2011 134

Figure 119: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Number of Licensing Deals By Value, 2005 – Q1 2011 135

Figure 120: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Type, 2009 – Q1 2011 136

Figure 121: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Geography, 2009 – Q1 2011 137

Figure 122: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Therapy Area, 2009 – Q1 2011 138

Figure 123: Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Phase, 2009 – Q1 2011 139

Figure 124: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Number of Licensing Deals, 2005 – Q1 2011 140

Figure 125: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Number of Licensing Deals By Value, 2005 – Q1 2011 141

Figure 126: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Licensing Deals By Type, 2009 – Q1 2011 142

Figure 127: Licensing Strategies in Large Pharmaceutical Companies, Baxter, Licensing Deals By Therapy Area, 2009 – Q1 2011 143

Figure 128: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Number of Licensing Deals, 2005 – Q1 2011 144

Figure 129: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Number of Licensing Deals By Value, 2005 – Q1 2011 145

Figure 130: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Type, 2009 – Q1 2011 145

Figure 131: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Geography, 2009 – Q1 2011 146

Figure 132: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Therapy Area, 2009 – Q1 2011 147

Figure 133: Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Phase, 2009 – Q1 2011 148

Companies Mentioned

GlaxoSmithKline

J&J

Roche

Abbott

Eli Lilly

Novartis

Sanofi

Takeda

Pfizer

Bristol-Myers Squibb

Boehringer-Ingelheim

Merck & Co.

Bayer

AstraZeneca

Astellas

Daiichi-Sankyo

Teva Pharma

Eisai

Baxter

Amgen

To order this report:

Therapy Industry: Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity

Therapy Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
3. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
4. Lilly and TransPharma Medical Announce Licensing and Development Agreement
5. Genzyme and Isis Complete Licensing of Mipomersen
6. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
7. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
10. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
11. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 According ... Research entitled "Brain Computer Interface Market - Global Industry Analysis, ... global brain computer interface (BCI) market  is expected to ... market is estimated to expand at a CAGR of ... 2024. A BCI device provides collaboration between ...
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Ischemic Stroke ...  report to their offering.       ... Global Acute Ischemic Stroke Market and ... into Acute Ischemic Stroke pipeline products, Acute ...
Breaking Medicine Technology:
(Date:5/5/2016)... Woodinville, WA (PRWEB) , ... May 05, 2016 ... ... better user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based ... easy-to-use computer and smart phone app. , The user interface of the app, ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week ... all over the United States to thank a nurse who's made a difference in ... $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) every ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy joints ... the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point ... arthritis. , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet ... weaken the immune system and increase inflammation, both of which raise the risk of ... congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead ...
(Date:5/5/2016)... ... May 05, 2016 , ... VisualDx announced today ... VisualDx is the first point of care diagnostic support system to be widely ... system speeds diagnosis, therapy decisions and patient education for emergency physicians, hospitalists and ...
Breaking Medicine News(10 mins):